These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 3893505)
21. [Prognostic significance of beta-2-microglobulin in multiple myeloma]. Podol'tseva EI; Morozova EV; Almazov VA Vopr Onkol; 1996; 42(4):32-5. PubMed ID: 8928455 [TBL] [Abstract][Full Text] [Related]
22. [Serum beta 2-microglobulin in multiple myeloma. I. Relation to selected indicators, clinical stage and disease prognosis]. Scudla V; Budíková M; Fischerová E; Raska I; Vavrdová V Vnitr Lek; 1991 Apr; 37(4):342-51. PubMed ID: 2053304 [TBL] [Abstract][Full Text] [Related]
23. Peripheral blood lymphocyte surface antigen expression and prognosis in myeloma: Australian Leukaemia Study Group Study. Joshua D; Wolf M; Matthews J; Tan L; Sheridan W; Pilkington G; Page F Leuk Lymphoma; 1994 Jul; 14(3-4):303-9. PubMed ID: 7950919 [TBL] [Abstract][Full Text] [Related]
24. Stratification of multiple myeloma according to serum beta 2-microglobulin and serum albumin levels. Scudla V; Budíková M; Fischerová E; Zadrazil J; Indrák K Acta Univ Palacki Olomuc Fac Med; 1991; 130():201-12. PubMed ID: 1838869 [TBL] [Abstract][Full Text] [Related]
30. Prognostic value of serum thymidine kinase and beta 2 microglobulin in subjects affected by multiple myeloma. Musolino C; Allegra A; Orlando A; Grosso P; Alonci A; Cincotta M; Squadrito G Riv Eur Sci Med Farmacol; 1990; 12(4-5):233-8. PubMed ID: 2103961 [TBL] [Abstract][Full Text] [Related]
31. Simple prognostic model for patients with multiple myeloma: a single-center study in Japan. Kaneko M; Kanda Y; Oshima K; Nannya Y; Suguro M; Yamamoto R; Chizuka A; Hamaki T; Matsuyama T; Takezako N; Miwa A; Togawa A Ann Hematol; 2002 Jan; 81(1):33-6. PubMed ID: 11807633 [TBL] [Abstract][Full Text] [Related]
32. Increased serum levels of beta2m-free HLA class I heavy chain in multiple myeloma. Perosa F; Luccarelli G; Prete M; Ferrone S; Dammacco F Br J Haematol; 1999 Sep; 106(4):987-94. PubMed ID: 10520002 [TBL] [Abstract][Full Text] [Related]
33. Time to first disease progression, but not beta2-microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy. Palumbo A; Bringhen S; Falco P; Cavallo F; Ambrosini MT; Avonto I; Gay F; Caravita T; Bruno B; Boccadoro M Cancer; 2007 Aug; 110(4):824-9. PubMed ID: 17594696 [TBL] [Abstract][Full Text] [Related]
34. Lymphoid subsets and prognostic factors in multiple myeloma. Cooperative Group for the Study of Monoclonal Gammopathies. San Miguel JF; González M; Gascón A; Moro MJ; Hernández JM; Ortega F; Jiménez R; Guerras L; Romero M; Casanova F Br J Haematol; 1992 Mar; 80(3):305-9. PubMed ID: 1581210 [TBL] [Abstract][Full Text] [Related]
35. Prognostic value of serum lactic dehydrogenase (S-LDH) in multiple myeloma. Simonsson B; Brenning G; Källander C; Ahre A Eur J Clin Invest; 1987 Aug; 17(4):336-9. PubMed ID: 3117570 [TBL] [Abstract][Full Text] [Related]
36. [Value of the determination of beta-2-microglobulin in the monitoring of myeloma. Apropos of 290 determinations]. Kaltwasser P; Sauger F; Le Loet X; Pasquis P; Monconduit M; Deshayes P Rev Rhum Mal Osteoartic; 1982 Apr; 49(5):359-63. PubMed ID: 6179150 [TBL] [Abstract][Full Text] [Related]
37. [Prognostic value of serum beta2-microglobulin in multiple myeloma]. Bettini R; Redaelli S; Maino C; Bertuol S; Costantini C; Lazzarini A; Brivio L; Gorini M Recenti Prog Med; 2005 Feb; 96(2):81-6. PubMed ID: 15844767 [TBL] [Abstract][Full Text] [Related]
39. Characterization of myeloma cells by means of labeling index, bone marrow histology, and serum beta 2-microglobulin. Schambeck CM; Bartl R; Höchtlen-Vollmar W; Wick M; Lamerz R; Fateh-Moghadam A Am J Clin Pathol; 1996 Jul; 106(1):64-8. PubMed ID: 8701935 [TBL] [Abstract][Full Text] [Related]